Comparative Pharmacology
Head-to-head clinical analysis: ADIPEX P versus OBESTIN 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADIPEX P versus OBESTIN 30.
ADIPEX-P vs OBESTIN-30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phentermine is a sympathomimetic amine that stimulates release of norepinephrine and to a lesser extent dopamine and serotonin from presynaptic nerve terminals in the hypothalamic feeding center, resulting in appetite suppression.
ObesTin-30 is a selective serotonin reuptake inhibitor (SSRI) that blocks serotonin reuptake, increasing serotonin levels in the synaptic cleft, which modulates appetite and mood.
Phentermine (ADIPEX-P) is typically dosed as 15–37.5 mg orally once daily, administered 2 hours after breakfast or before breakfast. The 37.5 mg tablet is taken once daily before breakfast or 1–2 hours after breakfast; some patients may require 15 mg or 30 mg (half of a 37.5 mg tablet) once daily. The extended-release formulation (ADIPEX-P) is not available; only immediate-release tablets are marketed. Duration of therapy should be limited to a few weeks (e.g., 4–12 weeks) due to potential for tolerance and abuse.
30 mg subcutaneously once daily.
None Documented
None Documented
Terminal half-life approximately 20-25 hours. Clinical context: Steady-state reached within 4-5 days; dosing adjustments may be needed in renal impairment.
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in patients with normal renal function; half-life may be prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (70-90% unchanged); minor biliary/fecal (10-30% as metabolites). Urinary pH-dependent; acidic urine increases excretion.
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose; fecal elimination via biliary excretion accounts for approximately 30%, with the remainder as metabolites.
Category C
Category C
Anorexiant
Anorexiant